Vospire Er Oral Tablet, Extended Release 4Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

VoSpire ER: Oral tablet, extended release (4mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_4669.JPG
Volmax 4mg ER Tablet
Muro Pharmaceutical Inc
Pill Identification: VOLMAX  |  4
Drug Image file DrugItem_7211.JPG
VoSpire ER 4mg Tab
Odyssey Pharmaceuticals Inc a Division of Teva USA
Pill Identification: 4  |  V
Drug Image file DrugItem_7542.JPG
VoSpire ER 4mg Tab
Qualitest, formerly Dava Brand Pharmaceuticals, Inc
Pill Identification: V  |  4
Drug Image file DrugItem_9031.JPG
Albuterol 4mg ER Tab
Mylan Pharmaceuticals Inc
Pill Identification: M  |  22
Drug Image file DrugItem_9132.JPG
Albuterol 4mg ER Tab
Qualitest, formerly Dava Pharmaceuticals Inc
Pill Identification: V  |  4

What is this Medicine?

ALBUTEROL (al BYOO ter ole) is a bronchodilator. It helps open up the airways in your lungs to make it easier to breathe. This medicine is used to treat and to prevent bronchospasm.

In-Depth Information
Select a Medication

VoSpire ER 4mg Extended-Release Tablet

NDC: 687740600
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Acute Bronchospasm, Asthma, Bronchospasm Prophylaxis

Sometimes used for but not FDA approved for the following conditions:
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)

Storage Information
Store at controlled room temperature (between 68 and 77 degrees F)
VoSpire ER 4mg Extended-Release Tablet
Drug Image file DrugItem_7542.JPG
Qualitest, formerly Dava Brand Pharmaceuticals, Inc
Pill Identification: V  |  4
Shape: round
Color: green

Reported Side Effects for VoSpire ER 4mg Extended-Release Tablet

Infection Incidence:
<21.0%*
Severity: MILD
Onset: DELAYED
Muscle Cramps Incidence:
<6.9%*
Severity: MILD
Onset: DELAYED
Incoordination Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Diaphoresis Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
<7.0%*
Severity: MILD
Onset: EARLY
Flushing Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Inflamed Tongue Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Hyperkinesis Incidence:
<4.0%*
Severity: MILD
Onset: DELAYED
Irritability Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Rapid Heart Rate Incidence:
<10.0%*
Severity: MODERATE
Onset: EARLY
Restlessness Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
<15.0%*
Severity: MILD
Onset: EARLY
Swelling Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Drowsiness Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Cough Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
High Blood Pressure Incidence:
<5.0%*
Severity: MODERATE
Onset: EARLY
Nervousness Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Ringing In Ears Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Shaking Incidence:
<37.9%*
Severity: MILD
Onset: EARLY
Retaining Urine Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Dry Mouth Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Enlarged Lymph Nodes Incidence:
0.9-2.6%*
Severity: MODERATE
Onset: DELAYED
Hives Incidence:
0.9-1.7%*
Severity: MILD
Onset: RAPID
Wheezing Incidence:
1.0-1.5%*
Severity: MODERATE
Onset: RAPID
Rapid Heart Rate Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: RAPID
Distressed Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Nightmares Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
1.0-3.0%*
Severity: MILD
Onset: DELAYED
Excitability Incidence:
1.0-20.0%*
Severity: MODERATE
Onset: EARLY
Emotional Lability Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
1.0-3.1%*
Severity: MILD
Onset: EARLY
Conjunctivitis Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Stuffy Nose Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Feeling Sick Incidence:
1.5%*
Severity: MILD
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
3.0-5.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
3.0-18.8%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
4.2-7.0%*
Severity: MILD
Onset: EARLY
Throat Irritation Incidence:
6.0-10.0%*
Severity: MILD
Onset: EARLY
Breathing Difficulties Incidence:
8.0-15.4%*
Severity: SEVERE
Onset: RAPID
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for VoSpire ER 4mg Extended-Release Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Caffeine-containing Foods/Beverages and VoSpire ER 4mg Extended-Release Tablet(Albuterol Sulfate)
Caffeine-containing Foods/Beverages and Beta-agonists(Albuterol Sulfate)
Limit excessive Caffeine intake (examples: coffee, teas, colas, chocolate and some herbal supplements) and limit medicines containing additional Caffeine. In caffeine-sensitive persons, taking a high amount of Caffeine with this drug can increase the risk of nausea, nervousness, palpitations, problems with sleep, rapid heartbeat, or other side effects.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with VoSpire ER

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5